Navigation Links
Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
Date:7/23/2008

gational medicines, two of which are in late stages of clinical testing. Duska's ATPace(TM) is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward- looking statements to be covered by the safe harbor provisions for forward- looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that Duska believes that the proposed single, prospective, placebo-controlled, and randomized trial in patients presenting to the emergency room with paroxysmal supraventricular tachycardia (PSVT) should be sufficient to demonstrate clinical safety and efficacy, that Duska believes that upon successful completion of the proposed Phase 3 trial, it would have all the clinical data necessary to support the filing of the NDA for ATPace(TM) under section 505(b)(2), the belief tha
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Duska Therapeutics Obtains Standard & Poors Listing
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
4. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
7. Organizational Changes at Silence Therapeutics
8. Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
9. Arno Therapeutics Announces New Ticker Symbol
10. Lorus Therapeutics Receives $600 Thousand From Escrow Account
11. Silence Therapeutics Announces Successful Opposition of Glover Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are currently ... seniors will die with Alzheimer’s or another dementia, according ... shocked many Americans into looking for ways to improve ... age-related cognitive disorders. Jonathan Weisman, president of Biohack Pure, ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... The " Anesthesia Drugs Market (2011 ... studies the U.S. market for intravenous anesthesia drugs with special focus on ... import system for controlled substances in U.S. and U.S. market entry strategy. ...   " Anesthesia Drugs Market (2011 - ...
... was able to reach for and sip from a drink on ... by using her thoughts to direct a robotic arm. ... is evaluating the safety and feasibility of an investigational device called ... brain-computer interface (BCI) intended to put robotics and other assistive technology ...
...  Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) announced ... Company,s common share repurchase program authorization by an additional ... 2008, the Company has returned $236 million to shareholders ... preferred shares, representing approximately 27% of its shares as ...
Cached Biology Technology:Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 2Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 2Paralyzed individuals use thought-controlled robotic arm to reach and grasp 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 4Paralyzed individuals use thought-controlled robotic arm to reach and grasp 5Questcor Pharmaceuticals Expands Repurchase Program 2Questcor Pharmaceuticals Expands Repurchase Program 3Questcor Pharmaceuticals Expands Repurchase Program 4Questcor Pharmaceuticals Expands Repurchase Program 5
(Date:4/20/2014)... breast and pancreatic cancers also promote drug-resistance and ultimately ... San Diego School of Medicine have discovered a molecule, ... tumors that appears responsible for inducing tumor metastasis by ... , The findings, published in the April 20, 2014 ... point to new therapeutic opportunities for reversing drug resistance ...
(Date:4/20/2014)... -- Using corn crop residue to make ethanol and ... greenhouse gases than gasoline, according to a study published ... , The findings by a University of Nebraska-Lincoln team ... be used to meet federal mandates to ramp up ... stover -- the stalks, leaves and cobs in cornfields ...
(Date:4/18/2014)... population predicted to reach 9 billion by 2050 ... considers human-altered landscapes such as farmland, according to ... that supports it might be an increasingly scarce ... of the land surface is directly affected by ... impacts such as climate change. But what if ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4
... of biodiversity, but there has been no effective way ... areas. As a result, we have limited understanding of ... are affecting these delicate ecosystems. A major advance in ... Asner of the Carnegie Institution,s Department of Global Ecology ...
... 2008) With the sequencing of the human genome ... a genes and other DNA sequences can vary widely between ... our species, genetic diversity but it has also been linked ... Harbor Protocols ( www.cshprotocols.org/TOCs/toc6_08.dtl ) features a new method ...
... the human malaria parasite, Plasmodium falciparum, which is responsible ... from becoming sexually mature. The discovery ... resistance, which is a major public health problem and ... cycle of Plasmodium falciparum is complex, and it is ...
Cached Biology News:Revolution in rain forest monitoring with MacArthur grant 2Cold Spring Harbor Protocols features methods for analyzing genomes and plant cells 2
... This CLS number is a new ... product number. If showing no availability yet, ... (C6421) or contact customer service for assistance. ... Comp Dim: surface area 21 cm ...
... Time-resolved microscopy is the ultimate tool for ... structures. Its applications previously have been limited ... microscope optics do not transmit in the ... in fluorescence spectroscopy, introduces a filter-based confocal ...
... using many of the automation concepts from ... requirements are similar to those for HTS: ... 24 or 48 wells with well volumes ... the number of wells has increased to ...
... Description: ,Kit containing Dermal Fibroblasts ... supplied as a long-term culture, and is ... of continuous growth from the date supplied, ... ,Source: Dermis, mouse/BalbC, embryonic day 18.5 ...
Biology Products: